You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

Drugs with Dosage: LIQUID


✉ Email this page to a colleague

« Back to Dashboard


Drugs with Dosage: LIQUID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration Dosage
Alra DIMENHYDRINATE dimenhydrinate LIQUID;ORAL 080715-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Trial ⤷  Free Trial ⤷  Free Trial LIQUID;ORAL
B Braun STERILE WATER IN PLASTIC CONTAINER sterile water for irrigation LIQUID;IRRIGATION 016734-001 Approved Prior to Jan 1, 1982 AT RX Yes No ⤷  Free Trial ⤷  Free Trial ⤷  Free Trial LIQUID;IRRIGATION
Baxter Hlthcare ETHRANE enflurane LIQUID;INHALATION 017087-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Trial ⤷  Free Trial ⤷  Free Trial LIQUID;INHALATION
Baxter Hlthcare FORANE isoflurane LIQUID;INHALATION 017624-001 Approved Prior to Jan 1, 1982 AN RX Yes Yes ⤷  Free Trial ⤷  Free Trial ⤷  Free Trial LIQUID;INHALATION
Baxter Hlthcare STERILE WATER sterile water for irrigation LIQUID;IRRIGATION 017428-001 Approved Prior to Jan 1, 1982 AT RX Yes No ⤷  Free Trial ⤷  Free Trial ⤷  Free Trial LIQUID;IRRIGATION
Baxter Hlthcare STERILE WATER IN PLASTIC CONTAINER sterile water for irrigation LIQUID;IRRIGATION 017866-001 Approved Prior to Jan 1, 1982 AT RX No No ⤷  Free Trial ⤷  Free Trial ⤷  Free Trial LIQUID;IRRIGATION
Bh HALOTHANE halothane LIQUID;INHALATION 084977-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Trial ⤷  Free Trial ⤷  Free Trial LIQUID;INHALATION
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration >Dosage

Market Dynamics and Financial Trajectory for Liquid Pharmaceutical Drugs

Introduction

The pharmaceutical industry is witnessing a significant shift towards liquid formulations, driven by several key factors that are transforming the market dynamics and financial trajectories of companies involved in this sector.

Rising Prevalence of Chronic and Acute Illnesses

The increasing prevalence of chronic and acute illnesses is a major driver for the growth of the liquid pharmaceutical drugs market. As the global population ages and the incidence of diseases such as diabetes, hypertension, and infectious diseases rises, the demand for effective and easily administered medications, including liquid formulations, is on the rise[1].

Growing Use in Liquid Pharmaceutical Formulations

Liquid pharmaceutical drugs, including water-soluble drugs, are gaining traction due to their enhanced bioavailability and quicker absorption rates compared to traditional solid forms. This makes them particularly appealing for patients who have difficulty ingesting tablets or traditional capsules, such as the elderly or those with certain medical conditions[4].

Increasing Pharmaceutical R&D Activities

The pharmaceutical industry is investing heavily in research and development (R&D) activities, with a focus on novel drug discovery and development. This includes the development of liquid-filled capsules and other innovative delivery systems that offer improved efficacy and patient compliance. Companies like Sanofi are collaborating with AI firms to accelerate drug development, which is expected to bring new medicines to patients more quickly[3].

Government Investments and Regulatory Support

Government investments in the life sciences industry are also bolstering the growth of the liquid pharmaceutical drugs market. Regulatory approvals and support for innovative drug formulations are crucial for the market's expansion. For instance, the EU approval of Dupixent for COPD and other conditions has significantly boosted sales for companies like Sanofi[3].

Market Segmentation and Key Players

Drug Type

The global water-soluble drugs market is segmented into paracetamol, antibiotics, and antihypertensive drugs. The antibiotics segment is expected to register the fastest revenue growth rate due to rising cases of infectious diseases and the growing demand for antibiotic drugs with improved efficacy and high bioavailability[1].

Route of Administration

Liquid pharmaceutical drugs can be administered orally or through intravenous injection. The oral route is particularly popular due to its ease of administration and patient compliance. Companies are focusing on developing oral liquid formulations that are both effective and convenient[1].

End-Use

The market is segmented by end-use into hospitals & clinics, ambulatory surgical centers, rehabilitation centers, homecare settings, and others. The increasing use of liquid pharmaceutical drugs in homecare settings is a significant trend, driven by the need for convenient and easy-to-administer medications[1].

Regional Market Dynamics

North America

North America dominates the global water-soluble drugs market, driven by the rising focus of pharmaceutical companies on enhancing drug solubility, increased use of water-soluble drugs in liquid formulations, and robust R&D activities. The US market, in particular, is a key driver, with companies like Sanofi and Servier experiencing significant revenue growth in this region[1][3].

Europe and Rest of the World

In Europe, while the market is growing, it faces challenges such as lower sales of certain medicines due to generic competition. However, the Rest of the World segment, including countries like China and Japan, is experiencing rapid growth driven by increasing health consciousness and the adoption of innovative drug delivery systems[3].

Financial Performance and Projections

Revenue Growth

The global water-soluble drugs market is expected to experience robust revenue growth, driven by the factors mentioned above. For instance, Sanofi reported a 10% sales growth in the second quarter of 2024, with significant contributions from liquid formulations like Dupixent[3].

Key Financial Indicators

  • Revenue: Companies like Servier reported overall revenue from brand-name medicines amounting to €4.041 billion for the 2022-2023 financial year, with a 9.4% increase relative to the previous year[2].
  • EBITDA: Servier's EBITDA stood at €1.015 billion for the 2022-2023 financial year, representing a 19.1% margin, up from 17.6% in the previous year[2].
  • Net Income: Despite some challenges, such as the impact of court decisions and increased tax expenses, companies are generally seeing positive net income trends driven by strong sales performance[2].

Technological Advancements

Technological advancements in capsule manufacturing, such as the development of moisture-resistant materials and improved encapsulation techniques, are enhancing product stability and efficacy. These advancements are crucial for the growth of the liquid-filled capsules market, which is a subset of the broader liquid pharmaceutical drugs market[4].

Challenges and Restraints

High Production Costs

One of the major challenges facing the liquid-filled capsules market is the high production cost associated with their manufacturing. This can limit accessibility for smaller manufacturers and startups, potentially hindering market growth[4].

Competition from Alternative Dosage Forms

The market also faces competition from alternative dosage forms such as tablets and powders, which may be perceived as more familiar or cost-effective by consumers. However, the unique benefits of liquid formulations, such as enhanced bioavailability and ease of administration, are helping to mitigate this competition[4].

Quotes from Industry Experts

"We are continuing our strong performance in 2024 and delivered broad-based, double-digit sales growth in the second quarter. We also made important progress in our pipeline of new medicines..." - Paul Hudson, Chief Executive Officer, Sanofi[3].

Illustrative Statistics

  • Revenue Growth: The antibiotics segment of the water-soluble drugs market is expected to register the fastest revenue growth rate, driven by rising cases of infectious diseases[1].
  • Sales Increase: Dupixent sales by Sanofi increased by 29.2% in the first quarter of 2024, reaching €3,303 million, with a projected annual sales figure of around €13 billion[3].
  • Market Expansion: The liquid-filled capsules market is expected to grow significantly, driven by increasing health consciousness and the rising demand for dietary supplements and medications[4].

Key Takeaways

  • The liquid pharmaceutical drugs market is driven by rising chronic and acute illnesses, increasing R&D activities, and government investments.
  • North America is the dominant region, with significant contributions from the US market.
  • Technological advancements in capsule manufacturing are enhancing product stability and efficacy.
  • High production costs and competition from alternative dosage forms are key challenges.
  • Companies like Sanofi and Servier are experiencing strong revenue growth and financial performance.

FAQs

What are the main drivers of the liquid pharmaceutical drugs market?

The main drivers include the rising prevalence of chronic and acute illnesses, increasing pharmaceutical R&D activities, and government investments in the life sciences industry.

Which segment of the water-soluble drugs market is expected to grow the fastest?

The antibiotics segment is expected to register the fastest revenue growth rate due to rising cases of infectious diseases and the growing demand for antibiotic drugs.

What are the key challenges facing the liquid-filled capsules market?

High production costs and competition from alternative dosage forms such as tablets and powders are major challenges.

How are technological advancements impacting the market?

Technological advancements in capsule manufacturing, such as the development of moisture-resistant materials and improved encapsulation techniques, are enhancing product stability and efficacy.

Which companies are leading in the liquid pharmaceutical drugs market?

Companies like Sanofi and Servier are prominent players in the market, with significant revenue growth and financial performance.

Sources

  1. Emergen Research, "Water-soluble Drugs Market, By Drug Type (Paracetamol, Antibiotics, Antihypertensive Drugs), By Route of Administration (Oral, Intravenous Injection), By End-use (Hospitals & Clinics, Ambulatory Surgical Centers, Rehabilitation Centers, Homecare Settings, Others), and By Region, Forecast to 2028".
  2. Servier, "Servier confirms its 2025 trajectory to achieve its 2030 ambition".
  3. Sanofi, "Sanofi Q2: strong performance with 10% sales growth; 2024".
  4. ResearchAndMarkets.com, "Liquid Filled Capsule Market - A Global and Regional Analysis: Focus on Product, Therapeutic Application, End User, and Country - Analysis and Forecast, 2024-2034".

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.